Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Paul M O'Byrne, Tony D'Urzo, Ekkehard Beck, Matjaž Fležar, Martina Gahlemann, Lorna Hart, Zuzana Blahova, Robert Toorawa, Kai-Michael Beeh, Paul M O'Byrne, Tony D'Urzo, Ekkehard Beck, Matjaž Fležar, Martina Gahlemann, Lorna Hart, Zuzana Blahova, Robert Toorawa, Kai-Michael Beeh

Abstract

Background: Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease.

Methods: Two multicentre studies examined the efficacy and safety of 4 weeks' once-daily (QD) olodaterol (2, 5, 10 and 20 μg, with background inhaled corticosteroids) in patients with asthma. One randomised, double-blind, parallel-group study (1222.6; 296 patients) administered treatment in the morning. Pulmonary function tests (PFTs) were performed pre-dose (trough) and ≤3 hours post-dose (weeks 1 and 2), and ≤6 hours post-dose after 4 weeks; primary end point was trough forced expiratory volume in 1 second (FEV1) response (change from baseline mean FEV1) after 4 weeks. A second randomised, double-blind, placebo- and active-controlled (formoterol 12 μg twice-daily) incomplete-block crossover study (1222.27; 198 patients) administered QD treatments in the evening. PFTs were performed over a 24-hour dosing interval after 4 weeks; primary end point was FEV1 area under the curve from 0-24 hours (AUC0-24) response (change from study baseline [mean FEV1] after 4 weeks).

Results: Study 1222.6 showed a statistically significant increase in trough FEV1 response with olodaterol 20 μg (0.147 L; 95 % confidence interval [CI]: 0.059, 0.234; p = 0.001) versus placebo, with more limited efficacy and no evidence of dose response compared to placebo across the other olodaterol doses (2, 5 and 10 μg). Study 1222.27 demonstrated increases in FEV1 AUC0-24 responses at 4 weeks with all active treatments (p < 0.0001); adjusted mean (95 % CI) differences from placebo were 0.140 (0.097, 0.182), 0.182 (0.140, 0.224), 0.205 (0.163, 0.248) and 0.229 (0.186, 0.272) L for olodaterol 2, 5, 10 and 20 μg, respectively, and 0.169 (0.126, 0.211) for formoterol, providing evidence of increased efficacy with higher olodaterol dose. Olodaterol was generally well tolerated, with a few events associated with known sympathomimetic effects, mainly with 20 μg.

Conclusions: The LABA olodaterol has >24-hour duration of action. In patients with asthma, evidence of bronchodilator efficacy was demonstrated with statistically and clinically significant improvements in the primary end point of trough FEV1 response measured in clinics over placebo for the highest administered dose of 20 μg in Study 1222.6, and statistically and clinically significant improvements versus placebo in FEV1 AUC0-24 responses at 4 weeks for all doses tested in Study 1222.27, which also exhibited a dose response. Bronchodilator efficacy was seen over placebo for all olodaterol doses for morning and evening peak expiratory flow in both studies. All doses were well tolerated.

Trial registrations: NCT00467740 (1222.6) and NCT01013753 (1222.27).

Figures

Fig. 1
Fig. 1
Designs of studies: (a) 1222.6 and (b) 1222.27. QD: once daily; BID: twice daily; ICS: inhaled corticosteroid
Fig. 2
Fig. 2
Patient disposition in studies: (a) 1222.6 and (b) 1222.27
Fig. 3
Fig. 3
FEV1 assessments in Study 1222.6. (a) Trough FEV1 response weeks 1–4 from baseline (±SE), (b) FEV1 profile over time at week 4 from baseline (±SE) and (c) FEV1 AUC0–3 response weeks 1–4 from baseline (±SE). FEV1: forced expiratory volume in 1 s; SE: standard error; AUC0–3: area under the curve from 0–3 hours
Fig. 4
Fig. 4
FEV1 assessments in Study 1222.27: adjusted mean FEV1 trough response at week 4. QD: once daily; BID: twice daily; PFT: pulmonary function test; FEV1: forced expiratory volume in 1 s

References

    1. Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20:1477–95. doi: 10.2174/0929867311320120003.
    1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2014. . Accessed 3 Mar 2015.
    1. Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58:4131–64. doi: 10.1021/jm5013227.
    1. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med. 2010;16:6–12. doi: 10.1097/MCP.0b013e32833303d2.
    1. Cazzola M, Calzetta L, Matera MG. β2-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4–17. doi: 10.1111/j.1476-5381.2011.01216.x.
    1. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155:291–9. doi: 10.1038/bjp.2008.284.
    1. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-h-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62. doi: 10.1124/jpet.110.167007.
    1. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600–9. doi: 10.1124/jpet.111.179259.
    1. O’Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, FitzGerald M, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124:1217–21. doi: 10.1016/j.jaci.2009.08.047.
    1. Ichinose M, Takizawa A, Izumoto T, Fukuchi Y. Efficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting β2-agonist, in Japanese patients with COPD [abstract A2931]. Am J Respir Crit Care Med. 2012;185.
    1. van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666–72. doi: 10.1016/j.pupt.2011.07.006.
    1. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord JA. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2 agonist, in patients with COPD [poster A2930]. Presented at the 103rd Annual International Conference of the American Thoracic Society, San Francisco, California, USA, 18–23 May 2012.
    1. Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–45. doi: 10.2147/COPD.S61717.
    1. Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419. doi: 10.1186/2193-1801-3-419.
    1. Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. doi: 10.2147/COPD.S62502.
    1. Lange P, Aumann J-L, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24 h lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. 2014;4:196.
    1. Beeh K-M, Beck E, Gahlemann M, Blahova Z, Toorawa R, Flezar M. Dose-finding study of 4-week, once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma [abstract A2764]. Am J Respir Crit Care Med. 2012;185.
    1. O’Byrne PM, D’Urzo T, Gahlemann M, Hart L, Wang F, Beck E. Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma [abstract A3963]. Am J Respir Crit Care Med. 2012;185.
    1. Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29:871–8. doi: 10.1183/09031936.00060006.
    1. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy. 2008;63:103–11. doi: 10.1111/j.1398-9995.2007.01555.x.
    1. Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40:570–9. doi: 10.1183/09031936.00121411.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit